Skip to content

Clinical trials

Breast Neoplasms trials in the United Kingdom

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Breast Neoplasms Country / region: United Kingdom Clear all

701 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20006
200112
200210
200317
200418
200517
200627
200736
200827
200929
201020
201123
201224
201328
201430
201526
201633
201731
201827
201935
202034
202131
202233
202328
202426
202528
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed368
Unknown status107
Active, not recruiting84
Recruiting70
Terminated59
Withdrawn6
Not yet recruiting4
Approved for marketing2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Hoffmann-La Roche59
AstraZeneca52
Novartis Pharmaceuticals43
Royal Marsden NHS Foundation Trust37
Pfizer27
Institute of Cancer Research, United Kingdom22
European Organisation for Research and Treatment of Cancer - EORTC17
Imperial College London15
GlaxoSmithKline14
Eli Lilly and Company13

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Breast Neoplasms701
Neoplasm Metastasis62
Neoplasms60
Ovarian Neoplasms37
Colorectal Neoplasms27
Triple Negative Breast Neoplasms27
Carcinoma, Non-Small-Cell Lung26
Prostatic Neoplasms26
Head and Neck Neoplasms16
Pancreatic Neoplasms16

Trials

Showing 1 to 25 of 701. Each trial links to its page on Pharma Observatory.

601 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.